Product information and disease descriptionProduct descriptionProduct informationPharmacology
Pharmacodynamics
7 evidence topics · 3 sources
Preclinical activity: CAR expression peaks on day 1 and BCMA-positive cells are killed
“To confirm function, the Descartes-08 RNA payload was electroporated into CD8+ T cells.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“CAR RNA was rapidly detected and then gradually waned to baseline (Fig. 1e), consistent with expression that peaked on day 1 (Fig. 1f).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Descartes-08 also efficiently depleted autologous PCs from healthy individuals or patients with MG (Fig. 1h,i and Supplementary Fig. 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Plasmablast BCMA and pDC activation markers after treatment compared with placebo: phase 2b
“Intriguingly, analysis of plasmablasts after Descartes-08 treatment revealed significant reductions in BCMA expression on plasmablasts at month 3 (n = 6) (P = 0.035) compared to placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Similarly, CD86 was significantly reduced on pDCs at month 1 (n = 11) (P < 0.001) relative to placebo and also trended downward at month 3 (Fig. 3e,f).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Interestingly, at month 12, the decrease in CD86 levels persisted among the Descartes-08 cohort (Extended Data Fig. 2), although fewer samples were available at month 12 (n = 7).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Despite the changes in activation state, the frequency of plasmablasts and circulating pDCs remained unchanged (Fig. 3g,h), consistent with the normal levels observed at screen (Fig. 3a,b).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Autoantibody repertoire and anti-AChR antibody titers: phase 2b
“By contrast, Descartes-08 was associated with a greater change in the autoreactome (r value median = 0.72) compared to placebo (r value median = 0.89) at month 3 compared to day 1; this change persisted through month 6 (r value median = 0.74) (Fig. 3j).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Furthermore, despite the dramatic changes in autoreactome, we did not observe a significant change in the anti-AChR antibody titer (Fig. 3m).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Anti-AChR antibody reductions in the phase 2a portion
Immune cell populations, immunoglobulins, and vaccine titers at month 3 and month 12: phase 2b
“In line with our hypothesis, no significant changes were observed between placebo and Descartes-08 when assessing broad immune populations, including the change in frequency of B cells, T cells, natural killer cells and monocytes (Fig. 4a–e and Supplementary Fig. 8).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Likewise, total immunoglobulins (Fig. 4f–h and Extended Data Table 3) and common vaccine titers (Fig. 4i–m and Extended Data Table 4) were preserved at month 3 and month 12.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Disease-associated cytokines after infusion: phase 2b
“Descartes-08 infusion was not associated with indicators of CAR-T cell therapy-induced inflammation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In particular, IL-6, IL-24, CCL19 and artemin (ARTN), all of which are involved in autoimmunity, decreased at month 3 as well as at month 1 and month 12 for some analytes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Importantly, IL-6 is a key indicator of MG severity, and this cytokine was significantly reduced at month 3 in patients receiving Descartes-08 (P = 0.019).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
T cell receptor repertoire after treatment
“TCR sequencing revealed that Descartes-08 increases clonal expansion and contraction compared to placebo (Fig. 6a,b).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Together, these data indicate that Descartes-08 alters the TCR repertoire without significantly changing the broader phenotypic composition of the T cell compartment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote